http://www.fpnotebook.com/
Chronic Lymphocytic LeukemiaAka: CLL
- Epidemiology
- Most common Leukemia in the United States
- Elderly patients (usually over age 50 years)
- More common in men
- Rare in Asian patients
- Pathophysiology
- Neoplastic accumulation of mature Lymphocytes
- Involves Blood and Bone Marrow
- May infiltrate spleen and lymph nodes
- Clonal B Lymphocyte mass involved in 95% of cases
- Chromosomal Abnormality: Trisomy 12
- Neoplastic accumulation of mature Lymphocytes
- Symptoms
- Signs
- Labs
- Peripheral Smear
- Leukocytosis
- Morphologically normal small Leukocytes
- Complete Blood Count
- Leukocyte count 15,000 to 200,000 (80-90% mature)
- Decreased Platelet Count
- Hemoglobin or Hematocrit consistent with Anemia
- Peripheral Smear
- Differential Diagnosis
- B-Cell CLL
- Reactive Lymphocytosis
- T-Cell CLL
- Sezary Syndrome
- Adult T-Cell Leukemia
- General
- Prolymphocytic Leukemia
- Lymphosarcoma Cell Leukemia
- Hairy Cell Leukemia
- Waldenstrom's Macroglobulinemia
- B-Cell CLL
- Complications
- Pancytopenia
- Coombs-positive Hemolytic Anemia (20%)
- Hypogammaglobulinemia
- Opportunistic infection
- Richter's Syndrome (evolves into aggressive Lymphoma)
- Autoimmune Thrombocytopenia
- Imaging
- Chest XRay
- Enlarged mediastinal lymph nodes
- Chest XRay
- Management
- Efficacy of treatment
- No regimen effective at eradicating CLL
- Goal is to reduce Leukemia cell mass and symptoms
- Alkylating Agents (pulsed q3-6 weeks or continuous)
- Indications
- Hemolytic Anemia and other cytopenia
- Disfiguring Lymphadenopathy
- Symptomatic organomegaly
- Marked systemic symptoms
- Agents
- Chlorambucil
- Cyclophosphamide
- Indications
- Glucocorticoids
- Coombs-positive Hemolytic Anemia
- Immune Thrombocytopenia
- Pancytopenia
- "Packed Marrow" Syndrome
- Splenectomy indications
- Hypersplenism
- Refractory Hemolytic Anemia
- Thrombocytopenia
- Radiation therapy indications
- Localized disease
- Palliative end-stage disease therapy (total-body)
- Immunoglobulin transfusion (not proven efficacious)
- Efficacy of treatment
- Course
- Indolent nature
- Often incidental finding on Complete Blood Count
- Staging and Prognosis
- Stage A: Lymphocytosis (<3 lymph node groups involved)
- Median survival: over 10 years
- Stage B: Lymphocytosis (>3 lymph node groups involved)
- Median survival: 5 years
- Stage C: Lymphocytosis with Anemia or Thrombocytopenia
- Median survival: 2 years
- Stage A: Lymphocytosis (<3 lymph node groups involved)
Leukemia, Lymphocytic, Chronic (C0023458) | |
|---|---|
| Definition (CSP) | chronic leukemia characterized by morphologically mature but immunologically less mature lymphocytes; manifested by an abnormal accumulation of these cells in blood, bone marrow, and lymphatic tissue. |
| Concepts | Neoplastic Process (T191) |
| ICD9 | 204.1 |
| English | B-cell chronic lymphocytic leukaemia/small lymphocytic lymphoma, B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma, Chronic lymphatic leukaemia, chronic lymphatic leukemia, Chronic lymphocytic leukaemia, Chronic lymphocytic leukemia, chronic lymphogenous leukemia, Chronic lymphoid leukaemia, Chronic lymphoid leukemia, CLL, CLL - Chronic lymphocytic leukaemia, CLL - Chronic lymphocytic leukemia, LEUKEMIA CHRONIC LYMPHOCYTIC, LEUKEMIA LYMPHOCYTIC CHRONIC |
| Spanish | leucemia linfatica cronica, leucemia linfocitica cronica, leucemia linfocitica cronica de linfocitos B/linfoma de linfocitos pequenos, leucemia linfoide cronica |
| Parent Concepts | Lymphoblastic Leukemia (C0023448), Chronic leukemia (category) (C1279296), Malignant Neoplasms (C0006826), Leukocyte Abnormalities, General and NEC (C0549532), Chronic lymphoid leukemia - category (C1531666), Mature (peripheral) B-cell neoplasm (C1532008), Duplicate concept (C1274013) |
| Sources | COSTAR, CSP, CST, DXP, ICD9CM, MTH, NDFRT, OMIM, PDQ, QMR, SCTSPA, SNOMEDCT Derived from the NIH UMLS (Unified Medical Language System) |